Antenatal malaria screening with a rapid diagnostic test (RDT) and treatment only of women with positive RDT findings may potentially prevent low birth weight resulting from malaria. The consequences of subpatent antenatal infections below the detection limit of RDTs are incompletely understood. In Malawi, pregnant women of any gravidity status were tested at each antenatal visit for Plasmodium falciparum, using an RDT and polymerase chain reaction analysis, and were followed until delivery. Associations between antenatal infections and delivery outcomes were assessed with Poisson regression or analysis of variance. Compared with women with no detected antenatal P. falciparum infection, women with positive RDT findings delivered babies with a lower mean birth weight (2960 vs 2867 g; mean difference, -93 g [95% confidence interval {CI}, -27 to -159]; P = .006); this was not observed among women with only subpatent infections (mean birth weight, 3013 g; mean difference, 54 [95% CI, -33-140]; P = .2268). These differences were apparent early in pregnancy, during the second trimester: compared with uninfected women, women with positive RDT findings delivered babies with a lower mean birth weight (mean difference, -94 g [95% CI, -31 to -156]; P = .003), but women with subpatent infections did not (mean difference, 36 g [95% CI, -49-122]; P = .409). Subpatent antenatal P. falciparum infections were not associated with adverse delivery outcomes. The association of patent infections at enrollment with low birth weight suggests the importance of preventing P. falciparum infection early in pregnancy.
Innovative approaches are continually needed to prevent placental malaria. In sub-Saharan Africa, placental Plasmodium falciparum infection causes low birth weight (LBW), small birth weight for gestational age (SGA), and preterm birth (PT); the risks of these adverse outcomes are mitigated by intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP), which, in Africa is widely recommended [1] but suboptimally administered [2, 3] and continually threatened by resistance to SP [4] [5] [6] . One possible alternative strategy to IPTp-SP is intermittent antenatal screening for parasites with rapid diagnostic tests (RDTs) and the treatment of women with positive RDT results (hereafter, "RDT-positive infections") with antimalarials (known as intermittent screening and treatment during pregnancy [ISTp] ). Although ISTp results in more maternal antenatal infections [7] , ISTp with artemisinin combination therapies was noninferior to IPTp-SP in preventing LBW in 2 trials in areas of low SP resistance in West Africa [7, 8] , and ISTp with dihydroartemisinin-piperaquine was inferior to IPTp-SP in preventing parasitemia at delivery in Kenya and Malawi [9, 10] . Although the World Health Organization (WHO) does not currently recommend ISTp as an alternative to IPTp-SP [11] , it is either being implemented [12] or planned [13] in settings of low-level malaria transmission. With broad declines in malaria transmission [14] and increasing resistance to SP [15] , ISTp may offer an alternative to IPTp-SP in some epidemiologic settings for the prevention of LBW in malaria-endemic Africa.
However, there exists concern that the ISTp approach may be undermined by low-density antenatal infections that are undetected by screening tests and therefore remain untreated. The lower limits of detection for P. falciparum vary by diagnostic method and are generally considered highest for light microscopy, slightly lower for RDTs, and lowest for molecular detection assays, such as polymerase chain reaction (PCR). Subpatent antenatal infections are defined as infections for which specimens are negative for parasites by light microscopy (hereafter, "microscopy-negative infections) or RDTs (hereafter, "RDT-negative infections") but positive for parasites by PCR (hereafter, "PCR-positive infections") and involve parasite densities that fall between the limits of detection of diagnostic methods. In cross-sectional studies, subpatent infections have been associated with pregnancy outcomes: they have been associated with maternal anemia during pregnancy [16] or at delivery [17] and with lower birth weight when detected at delivery [18, 19] . These cross-sectional studies provide limited ability to infer causality, but only a limited number of longitudinal studies have investigated subpatent infections and delivery outcomes. In Benin, these submicroscopic infections were associated with higher risks of LBW and PT [20] and, in Malawi, with an increased risk of placental malaria but not adverse maternal or fetal outcomes [21] . In one Ghanaian study, RDT-negative antenatal infections were not associated with LBW [22] . Before ISTp can be considered as a potential viable alternative to IPTp in any settings, the potential impact of subpatent infections, especially RDT-negative infections, on a variety of end points in multiple cohorts needs to be determined.
We investigated the impact of subpatent (ie, RDT-negative and PCR-positive) P. falciparum infections in a cohort of Malawian women who were enrolled in a trial and randomly assigned to the arm that received ISTp, using a commercial RDT that detects the Plasmodium antigens HRP2 and pLDH [10] . We tested the impact of antenatal subpatent infections on maternal and newborn birth outcomes, including birth weight, gestational age, placental malaria, and maternal hemoglobin level at delivery. We hypothesized that, relative to uninfected women, the presence of subpatent antenatal infections would be associated with a decrease in mean birth weight and with growth retardation, particularly among infants born to paucigravidae.
METHODS

Study Cohort
We used specimens collected from participants in a published randomized clinical trial in Malawi conducted between 2011 and 2014 that compared IPTp-SP to ISTp-DP (Pan African Clinical Trials Registry no. 201103000280319; ISCRTN Registry no. 69800930) [10] . Briefly, women with any number of past pregnancies who were presenting for antenatal care between gestation weeks 16 and 28 to 3 health clinics in southern Malawi were eligible to participate. Women were randomly assigned at a ratio of 1:1 to either intervention, which was administered in an open-label fashion. Before delivery, all women were seen again at 2-3 additional scheduled visits and were encouraged to return for unscheduled visits if they felt unwell between scheduled visits.
We used specimens only collected from women allocated to receive ISTp. At each visit, venous blood specimens were collected from these women for parasite detection by light microscopy, RDT, and PCR. Those who tested positive by RDT were administered a standard 3-day course of dihydroartemisinin-piperaquine.
Outcome Assessments
At delivery, a maternal venous blood specimen was tested for parasites, using the same methods; placental histologic analysis was performed to determine the presence of placental malaria, using standard methods [23] ; placental blood from the maternal side was tested for malaria parasites by using light microscopy, RDT, and PCR; newborns were weighed, and gestational age was assessed using a modified Ballard score [24] . The maternal hemoglobin level was measured in venous blood specimens, using the Hemocue 301 system; a hemoglobin concentration of <11 g/dL defined maternal anemia.
Birth weights obtained >24 hours after birth were corrected for the physiologic fall in weight in breastfed children [25] to obtain a corrected birth weight, which was used in all analyses. Birth weights were measured using digital weigh scales reporting weight to the nearest 10 g. LBW was defined as a birth weight of <2500 g. We estimated gestational age by using the following hierarchy, which varied between participants: ultrasonography findings at enrollment, modified Ballard score obtained during clinical examination of the newborn within 96 hours of delivery, last menstrual period before pregnancy, or fundal height at enrollment. PT was defined as delivery before gestation week 37. SGA was defined as a birth weight below the tenth percentile for the gestational age and sex of the newborn, using a Tanzanian reference population; from this reference, z scores of birth weight for gestational age were computed [26] .
Laboratory Procedures
Microscopy was performed at a central laboratory at the University of Malawi by 2 independent readers who assessed 200 high-powered fields of thick-smear preparations. A positive microscopy finding was defined as the presence of any asexual Plasmodium parasites. RDTs were performed at the point of care by using the HRP2/pLDH combination RDT (FirstResponse Malaria pLDH/HRP2 Combo Test, Premier Medical Corporation) per the manufacturer's recommendation. A positive test result was defined as the presence of the control band and at least 1 HRP2 or pLDH band. Placental sections of 2.5 cm 3 were used for histologic analysis, for which hematoxylin-eosin staining was used to score for the presence of parasites, parasite pigment, and intervillous inflammation [23] ; histologic analysis was performed by a trained technician masked to microscopy, RDT, and outcome data.
PCR detection of parasites was performed using a real-time PCR assay [27] targeting the P. falciparum lactate dehydrogenase gene (pfldh) in genomic DNA extracted from dried blood spots by using Chelex-100. Real-time PCR assays were performed in duplicate in 384-well reaction plates on a BioRad CFX384 platform, threshold lines were set manually, and each reaction plate included genomic DNA from parasite strain 3D7 as a positive control. PCR detection was performed by personnel masked to microscopy, RDT, and outcome data.
Data Analyses
The main exposure of interest was subpatent (ie, RDT-negative and PCR-positive) infection with P. falciparum. Exposure classifications were (1) infections at antenatal enrollment, based upon RDT and PCR findings (no infection vs RDT-positive infection vs subpatent infection) and (2) cumulative antenatal infections (no history of infection vs RDT-positive infection only vs subpatent infection only). The continuous outcomes analyzed were maternal hemoglobin level at delivery, birth weight, gestational age, and birth weight for age z score; the dichotomous outcomes analyzed were LBW, SGA, PT; the composite end point of LBW, SGA, or PT; placental malaria (parasites detected by microscopy, RDT, PCR, or histologic analysis of placental specimens); and maternal anemia at delivery (hemoglobin concentration, <11 g/dL). We compared continuous outcomes by using 1-way analysis of variance and expressed results as the mean difference and corresponding 95% confidence intervals (CIs). We compared dichotomous outcomes by using Poisson regression and expressed results as risk ratios (RRs) with 95% CIs. We compared proportions of placental histologic features between groups using the chi-squared test. All analyses were conducted overall (all gravidae) and by gravidity strata (paucigravidae and multigravidae). The analysis involving all gravidae included gravidity as a binary covariable (paucigravida or multigravida). All statistical analyses were performed with Stata/IC (v14; StataCorp, College Station, TX).
Ethical Statement
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RESULTS
Epidemiology of Antenatal P. falciparum Infections
Of 923 women allocated to the ISTp study arm, the mean age (±SD) was 22.5 ± 5.1 years, the mean estimated gestational age at enrollment (±SD) was 146.8 ± 23.3 days, 34% were primigravidae, and 18% had slept under a bed net the previous night. At enrollment, 51.2% (473) were uninfected, 34.5% (318) had an RDT-positive infection, and 14.3% (132) had a subpatent infection. The prevalences of RDT-positive infections were lower at subsequent scheduled visits, with values of 6.1% at the first visit, 7.0% at the second, and 10.3% at the third. In contrast, the prevalence of subpatent infections remained largely unchanged at these visits, with values of 12.5% at the first, 13.2% at the second, and 14.3% at the third ( Figure 1A) . At unscheduled visits, the prevalence of RDT-positive infections was higher than that of subpatent infections ( Figure 1A ).
Overall, women had RDT-positive infections on up to 4 separate visits and subpatent infections on up to 6 separate visits ( Figure 1B ). Of the 923 women, 474 (51.4%) had at least 1 RDTpositive infection, and 323 (35%) had at least 1 subpatent infection. Compared with multigravidae, paucigravidae did not have more subpatent infections (prevalence, 36.4% among paucigravidae and 32.7% among multigravidae; P = .47).
Maternal and Newborn Outcomes
The overall mean birth weight (±SD) was 2921 ± 423 g, mean maternal hemoglobin level at delivery (±SD) was 12 ± 1.56 g/ dL, mean gestational age (±SD) was 38.1 ± 2.4 weeks, and mean birth weight for age z score (±SD) was 0.14 ± 0.94 (Supplementary Table 1 Figure 3 and Supplementary Table 2 ).
Associations of Birth Outcomes With Cumulative Antenatal Infections
Compared with infants born to women who were never infected, women with RDT-positive infections during pregnancy delivered babies with lower birth weights (mean difference, -93 g [95% CI, -159 to -27]; P = .0061) and birth weight for age z scores (mean difference, -0.20 [95% CI, -.34 to -.05]; P = .008); in contrast, neither outcome was associated with having had only subpatent infections ( Figure 2 and Supplementary Table 3 ). In analyses stratified by gravidity, compared with women who were never infected, RDT-positive infections were associated with nonsignificant reductions in mean birth weight among both paucigravidae (mean difference, -39 g [95% CI, -129-50]; P = .3916) and multigravidae (mean difference, -79 g [95% CI, -184-25]; P = .1369), while subpatent infections were associated with nonsignificant increases in birth weight (Supplementary Table 3) . Notably, there were no differences in gestational age between women who were never infected and those who had either RDTpositive infections or subpatent infections only. There was no statistically significant difference in the prevalence of LBW between those who were never infected (9.7%), those with RDT-positive infections ( Gestational age (weeks) Birth weight for age z score 
DISCUSSION
In our cohort of >800 delivering women in a malaria-hyperendemic setting in Malawi, PCR-positive subpatent antenatal P. falciparum infections, in which parasite levels were below the limit of detection of an RDT and infections therefore remained untreated, were not consistently associated with adverse maternal or newborn outcomes. In contrast, RDT-positive infections were, as expected, associated with lower birth weights and lower birth weight for age z scores, suggesting that antenatal 
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P. falciparum infections that remain undetected by a commercial RDT targeting the pLDH/HRP2 antigens are not associated with an increased risk of adverse clinical birth outcomes. This lack of an association between morbidity and subpatent infections was evident in multigravidae, as well as in paucigravidae, although paucigravidae are at higher risk of malarial infections and their consequences. Our results are consistent with a prior Ghanaian trial of ISTp with artemether-lumefantrine in paucigravidae, which also showed no associations between subpatent infections and birth weight or maternal hemoglobin concentration [22] . Taken together, these data, coupled with our analyses of a broad range of outcomes in a cohort with a high prevalence of subpatent infections, suggest that untreated subpatent infections do not cause fetal growth restriction or maternal anemia in semiimmune pregnant women in areas of sub-Saharan Africa where malaria is highly endemic. Furthermore, our data do not support the hypothesis that the nonsuperiority of ISTp-DP to IPTp-SP was mainly the result of a failure to detect and treat these subpatent infections. The continued efficacy of IPTp-SP to improve birth weight may be the result of off-target or antibacterial effects of SP or cryptic factors.
Unlike a recent study in Benin [20] , we found no specific association between subpatent infections at antenatal enrollment and an increased prevalence of LBW or PT. Both our study and the study in Benin enrolled women before gestation week 24 and detected parasites by using real-time PCR assays, but key differences are the use of IPTp with SP in Benin and the differing definitions of "subpatent" between the 2 studies (submicroscopic infections in Benin and RDT-negative infections in our study). Both of these differences might be expected to exacerbate the biological effects of subpatent infections in our study: the absence of IPTp in our study would have allowed subpatent infections to persist during pregnancy, and the higher limit of detection of parasites for our RDT (approximately 200 parasites/μL) [28] as compared to microscopy (reported as 40 parasites/μL) [20] would permit higher-density infections to be classified as subpatent. Nevertheless, we observed no consistent impact of these RDT-negative infections.
Antenatal P. falciparum infections should offer a unique model by which to investigate the individual clinical impact of subpatent infections by means of the analysis of birth outcomes, but in light of our null results and those of Williams et al [22] , what is the biological importance of RDT-negative infections? In a longitudinal study of Ugandan children [29] , subpatent (ie, microscopy-negative and PCR-positive) P. falciparum infections were not associated with an increased risk of clinical disease, relative to uninfected children, suggesting that low-density subpatent infections may not presage clinical consequences. One hypothesis for this phenomenon in children is that low-density infections may promote or maintain adaptive immunity to clinical disease [30] . By analogy, the presence of subpatent antenatal infections may promote the acquisition of immunity to placenta-binding parasites, which develops during pregnancy in Malawian paucigravidae [31] and is associated with protection from adverse birth outcomes [32] . Notably, although we observed a higher prevalence of placental malaria in women with subpatent infections as compared to those who were never infected, the prevalence was similar between groups of malaria parasite pigment, which has been associated with low birth weight in prior studies [23] . Therefore, partial immunity promoted by subpatent parasites could potentially attenuate the downstream effects of placental malaria and limit its deleterious impact on birth weight.
Our results further highlight the need to prevent patent infections early in pregnancy. Compared with uninfected women, those harboring RDT-positive infections at enrollment delivered infants with lower birth weights and birth weight for age z scores despite being treated with DP at that visit and being screened subsequently for parasites with RDTs. In our study, women were enrolled between gestation weeks 16 and 24, and there were no associations between antenatal or enrollment infections and gestational age, indicating that lower birth weights were likely the result of intrauterine growth retardation. Therefore, the associations with birth weight likely reflect the vulnerability of the placenta to parasitization during the first and early second trimesters, when placental pathology can disrupt the trajectory of fetal growth. Currently, with the exception of insecticide-treated net, antenatal malaria prevention is initiated during the second trimester owing to care-seeking customs and the contraindication to SP use in the first trimester [33] . Our data, taken together with similar findings in Benin [20] , suggest that the risk of LBW and placental malaria may be further reduced by initiating preventive measures earlier in pregnancy. This may be enhanced by recent changes to the WHO's antenatal care guidelines, which now recommend a minimum of 8 antenatal care visits and encourage contacts at gestation week 13 to promote IPTp [34] . Two additional points merit mention. The prevalence of antenatal subpatent infections remained largely unchanged, varying between 12% and 14% of women at each scheduled antenatal visit; this is in contrast to the prevalence of patent infections, which were most common at antenatal enrollment and uncommon thereafter, likely owing to the treatment of these RDTpositive women with DP. Although the direct effect of these subpatent infections on birth outcomes was not apparent in our study, ongoing gametocytemia may allow these women to remain reservoirs of overall malaria transmission. Second, the prevalence of placental malaria, as detected by microscopy, RDT, PCR, or histologic analysis, was 24% in the 242 women who tested negative by all methods at each visit; by comparison, the prevalence was 35% in women randomly assigned to receive IPTp-SP in this study. This suggests that screening and treating in the second trimester, using any diagnostic method or treatment, will still result in a large proportion of women with placental infection. Therefore, prevention, using bed nets and routine use of highly effective prophylaxis or more-effective antimalarials such as dihydroartemisinin-piperaquine for IPTp, may be more-effective measures to reduce placental malaria.
In this cohort of pregnant Malawian women who were screened 3-4 times during the second and third trimester for malaria parasites by using RDTs and who did not receive standard intermittent preventive antimalarial therapy, antenatal subpatent P. falciparum infections were common but not associated with adverse maternal or newborn delivery outcomes. In contrast, RDT-positive infections were associated with lower mean birth weights and a higher prevalence of LBW, and this association was already apparent at enrollment in the second trimester. These findings suggest that higher-density infections may account for the adverse sequelae of antenatal malarial parasite infection and that the prevention of these infections early in pregnancy may offer a new strategy to improve existing antenatal care programs in malaria-endemic Africa.
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